Viz HCM vs Zio AT ECG Monitoring System

Viz HCM streamlines clinician workflows within a hospital setting through EHR/PACS integration and AI-powered documentation assistance. Zio AT, while also offering a clinician portal, places a strong emphasis on patient usability with a comfortable wearable patch and a patient mobile app for at-home monitoring, designed for a 'tech adverse population'. By explicitly addressing ease of use for both clinicians and patients, Zio AT demonstrates a broader focus on overall usability.

Both tools are FDA-cleared and backed by extensive clinical evidence. Viz HCM is the 'first and only FDA-cleared AI algorithm for HCM', specifically designed for real-time detection of a serious, often undiagnosed condition, significantly reducing diagnosis time from years to a mean of 37 days. Zio AT offers valuable long-term arrhythmia detection, but Viz HCM's targeted impact on a critical, challenging diagnosis with proven time reduction gives it a slight edge in specific clinical value.

Viz HCM provides clear pricing transparency, stating it is subscription-based for health systems and detailing specific CMS reimbursement codes and rates, effective January 1, 2025. This explicit information allows potential customers to readily assess the financial value. In contrast, Zio AT's pricing is not publicly disclosed, requiring direct contact for details, which makes an upfront value assessment more challenging.

Both tools are FDA-cleared, HIPAA compliant, BAA-available, and cloud-based. Viz HCM integrates with EHR and PACS across many hospitals. However, Zio AT stands out by being the 'first medical device company to offer service through the Epic Aura network', providing a highly streamlined and efficient EHR integration process that can save significant time for health systems. This pioneering integration with a major EHR vendor demonstrates a superior level of enterprise readiness for seamless adoption.

Both tools are innovative. Viz HCM's innovation lies in its real-time AI detection of a specific, complex, and often missed condition (HCM) from standard ECGs, coupled with automated care coordination. Furthermore, its recent introduction of Viz Assist, an autonomous AI agent platform leveraging large language models for automated documentation and insights, represents a significant advancement in reducing clinician burden and enhancing workflow. Zio AT's innovation is in its patient-friendly wearable for long-term, continuous arrhythmia detection, but Viz HCM's multi-faceted AI application for both diagnosis and workflow optimization gives it a slight lead.

Viz HCM offers dedicated customer success teams, clinical specialists, and an academy for training and education. Zio AT provides 24/7 support for both patients and providers via phone and email, along with comprehensive clinical reference manuals and patient education resources. The explicit 24/7 availability for both key user groups, coupled with detailed patient-focused documentation, suggests a slightly more comprehensive and accessible support ecosystem for Zio AT.